DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Eli Lilly - 2 Lilly - 2 Seamus Fernandez - 2 Morgan Stanley - 2 Terence Flynn - 2 Morgan Stanley's Flynn - 2 David Risinger - 1 Mounjaro - 1
Top related locs:
U.S GLP
Top related orgs:
Investment - 1 Food - 1 Leerink - 1 Novo Nordisk's - 1 FDA - 1 Kisunla - 1 Wall - 1 Novo - 1

Search resuls for: "Morgan Stanley's Flynn"


2 mentions found


☆ Eli Lilly shares could be set for a big move if the Zepbound maker adds to its winning streak
  + stars: | 2024-10-29 | by ( Christina Cheddar Berk | In | ) www.cnbc.com   time to read: +6 min
Revenue from obesity treatment Zepbound is forecast to climb to $1.73 billion from $1.24 billion quarter over quarter. For the year, analysts expect Mounjaro sales to reach $4.58 billion, while Zepbound revenue is seen rising to $5.88 billion. The consensus view for combined sales of both drugs now stands at $30.19 billion, according to FactSet. Other key announcements A clinical trial is in progress that pits Zepbound against Novo Nordisk's Wegovy in obesity treatment. Beyond obesity, Lilly has begun treating patients with Kisunla, its Alzheimer's disease treatment.
Persons: Eli Lilly, Lilly, Seamus Fernandez, Morgan Stanley, Terence Flynn, David Risinger, Morgan Stanley's Flynn, Mounjaro, Cantor, Louise Chen, —, Fred Imbert Organizations: Investment, Food, Leerink, Novo Nordisk's, FDA, Kisunla Locations: U.S
☆ Analysts predicted new obesity medicines would be blockbusters. Now they’re raising their forecasts
  + stars: | 2023-09-16 | by ( Christina Cheddar Berk | ) www.cnbc.com   time to read: +9 min
Fernandez sees a total addressable market of $140 billion to support patients with obesity. He expects there is a potential for GLP-1 drugs to become as common and widely used, much like statins are used to lower cholesterol. Morgan Stanley's Flynn estimates a 30% share of the diabetes market would generate $109 billion on a worldwide basis for GLP-1 drugs. Layer in a 15% to 30% share of the obesity market and that equates to worldwide sales of $97.4 billion to $194.8 billion. Guggenheim's estimates also assume that oral GLP-1 drugs that are currently in development are able to come to market a few years from now.
Persons: Seamus Fernandez, Fernandez, Lilly, Eli Lilly, Morgan Stanley, Terence Flynn, Eli Lilly's Mounjaro, Insulet, Canaccord, William Plovanic, Plovanic, It's, Morgan Stanley's Flynn, Flynn, Novo, Michael Bloom Organizations: Wall, Novo, American Heart Association, Food and Drug Administration, Novo Nordisk, Iqvia, Disease Control Locations: GLP
0 next >>
Total: 2